As the initial market response to its new 5G system-on-chip (SoC) solutions appears to be positive, 5G represents an opportunity for MediaTek Inc (聯發科) to increase the average selling prices (ASPs) of its products and boost its earnings, analysts said.
Moreover, MediaTek is likely to see its 5G SoC solutions gain better traction among Chinese smartphone original equipment manufacturers (OEMs) beginning next year, they said.
“MediaTek’s 5G SoC development is on schedule and should pave the way for its smooth transition into the 5G era in 2020 and let it capture demand tied to the coming 5G-driven handset replacement cycle,” SinoPac Securities Investment Service Corp (永豐投顧) said in a research note released on Monday.
“The de-Americanization of Chinese vendors’ supply chains would also help boost its handset SoC shipments and stabilize its market share,” SinoPac said.
MediaTek is planning to mass-produce its first 5G SOC product in March next year, making it one of the world’s leading suppliers of 5G chips.
MediaTek’s shipments of 5G chips are likely to reach 30 million units next year and grow to 75 million units in 2021, Credit Suisse Group AG said in a report on Tuesday.
China’s Oppo Mobile Telecommunications Corp (歐珀), Vivo Communication Technology Co (維沃) and Xiaomi Corp (小米) are likely to become MediaTek’s major clients for 5G chips next year, while Huawei Technologies Co (華為) and Samsung Electronics Co might increase their orders in 2021, Credit Suisse said.
While 5G opportunities look good from next year onward, aggressive 5G pricing from Qualcomm Inc or a slower 5G adoption rate in China due to trade disputes with the US might pose potential risks for MediaTek, analysts said.
The company on Wednesday reported that its revenue increased 1.95 percent month-on-month and 1.69 percent year-on-year to NT$23.49 billion (US$761.43 million) last month, the most in 13 months.
Last month’s revenue growth helped lift the company’s third-quarter revenue to NT$67.22 billion, which was in line with the revenue forecast of NT$65.3 billion to NT$70.2 billion that MediaTek made in July.
In the first three quarters of the year, total revenue reached NT$181.51 billion, an increase of 2.45 percent compared with NT$177.17 billion in the same period last year.
So far this year, MediaTek’s sales were evenly distributed amid the company’s three major business segments — mobile computing; growth solutions, including Internet of Things and power management IC; and mature solutions such as television SoC — and all three segments’ ASPs and gross margins expanded from a year earlier, SinoPac said.
SinoPac gave MediaTek a long-term “buy” rating with a target stock price of NT$490, which was set based on a price-to-earnings ratio of 25, compared with its previous target price of NT$366 based on a price-to-earnings ratio of 22.
Credit Suisse maintained its “outperform” rating on the stock, but raised its target price on MediaTek from NT$365 to NT$440, and forecast earnings per share of NT$19.71 for next year.
MediaTek shares closed at NT$372 on Wednesday in Taipei trading. The stock has risen 62.09 percent since the beginning of this year, outperforming the broader market’s 11.95 percent increase over the period.
Malaysia is scrambling to protect its assets as the descendants of the last sultan of the remote Philippine region of Sulu look to enforce a US$15 billion arbitration award in a dispute over a colonial-era land deal. In 1878, two European colonists signed a deal with the sultan for the use of his territory in present-day Malaysia — an agreement that independent Malaysia honored until 2013, paying the monarch’s descendants about US$1,000 per year. Now, 144 years later after the original deal, Malaysia is on the hook for the second-largest arbitration award on record for stopping the payments after a bloody incursion
RECOVERED CONFIDENCE: As market rationality returns, Taiwanese stocks that have lagged behind their US peers might soon catch up, Allianz researchers said Local shares last week defied heavy pressure from China’s military drills in waters around Taiwan, and investors this week are expected to pay attention to earnings results from several tech heavyweights as well as the latest economic data on exports and GDP. The TAIEX closed at 15,036.04 points on Friday, posting a weekly increase of 0.24 percent from 15,000.07 on July 29, Taiwan Stock Exchange data showed. Over the same period, the FTSE TWSE Taiwan 50 Index, which comprises Taiwan’s top 50 stocks in terms of market capitalization, closed up 0.93 percent at 11,750.15 points, while the Formosa Stock Index, which measures
Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms. The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors. The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times
FORECAST EXCEEDED: China’s curbs on some Taiwanese goods are unlikely to affect trade given inter-reliance in the electronics industries, a finance ministry official said Exports last month spiked 14.2 percent to US$43.32 billion, the second-highest increase on record and the 25th consecutive month of gains, driven by global demand for electronics used in high-performance computing and vehicles, the Ministry of Finance said yesterday. The ministry expects the trend to sustain this month and beyond, although the pace could slow due to inventory corrections for laptops, smartphones and other consumer electronics. “The July results proved stronger than expected despite rising fears over economic uncertainty,” Department of Statistics Director-General Beatrice Tsai (蔡美娜) said, adding that a high sales season in the West and stabilized COVID-19 infections in China
RSS